Misleading annual charge, unclear clinical process, and unanswered medication questions
I purchased what I understood to be a one-year semaglutide treatment plan from SnagRx for $828, with medication shipped monthly. I paid using my FSA card because I believed I was paying for medical treatment and medication.
After the charge went through, my FSA administrator determined that the entire $828 was ineligible, identifying the charge as a membership fee rather than an eligible medical expense. This was especially concerning because the way the program was presented led me to understand that I was purchasing a year of treatment including medication, rather than paying an $828 membership fee.
I immediately requested cancellation and a refund. At that point, I had received no medication. Nevertheless, obtaining a refund has been extremely difficult, even after I explained that my FSA administrator requires the ineligible funds to be returned.
I also became increasingly concerned about the clinical process. I could not find a way to schedule an initial consultation with a clinician online, nor could I find a straightforward way to contact the clinical team directly with questions before proceeding.
I also received dosing information that appeared unusual compared with the standard once-weekly dosing of FDA-approved semaglutide products, which raised questions I wanted to discuss with a clinician. In addition, I specifically tried to verify whether the compounded semaglutide being supplied was semaglutide base or a salt form, and I was unable to obtain satisfactory verification before medication was to be dispensed.
For a compounded prescription medication, I believe patients should be able to obtain clear answers about what formulation they are receiving, who is prescribing it, what pharmacy is dispensing it, and why a particular dosing regimen is being prescribed before paying for a year of treatment.
I have now spent significant time communicating with SnagRx and my FSA administrator and pursuing outside consumer-complaint options over a transaction I attempted to cancel before receiving medication.
I will update this review if SnagRx refunds the $828 or otherwise resolves the situation. Until then, I recommend that anyone considering the annual program—especially anyone planning to use an FSA or HSA—get everything in writing before paying, including what the annual charge represents, FSA/HSA eligibility, cancellation terms, the dispensing pharmacy, the exact compounded formulation, dosing instructions, and how to speak with the prescribing clinician.
18. September 2026
Bewertung ohne vorherige Einladung